• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Clene Inc. (Amendment)

    2/13/24 5:05:49 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLNN alert in real time by email
    SC 13G/A 1 ea193544-13ga1vivo_clene.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

    Clene, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    185634102

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)

     

      þ Rule 13d-1(c)

     

      ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1.

    NAMES OF REPORTING PERSONS

     

    Vivo Opportunity Fund Holdings, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     (a) ☐

     (b) þ

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    12,500,000 (1)(2)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    12,500,000 (1)(2)

    8.

    SHARED DISPOSITIVE POWER

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    12,500,000 (1)(2)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

     

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    7.0% (2)

    12.

    TYPE OF REPORTING PERSON

     

    PN

     

    (1) The number represents (i) 6,250,000 shares of common stock, par value $0.0001 per share (the “Common Stock”) of Clene, Inc. (the “Issuer”) issuable upon exercise of Tranche A warrants that are exercisable within 60 days of this Statement, and (ii) 6,250,000 shares of Common Stock issuable upon exercise of Tranche B warrants that are exercisable within 60 days of this Statement.  All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The Tranche A warrants and Tranche B warrants contain provisions preventing the warrants from being exercised if such exercise would result in the holder obtaining greater than 9.99% of the Issuer’s voting securities.

     

    (2)

    Based on 167,095,337 shares of the Issuer’s Common Stock to be outstanding after the at the market offering of the Issuer, as disclosed in the prospectus filed by the Issuer on November 7, 2023, pursuant to Rule 424(b)(5), which forms part of the Issuer’s Registration Statement on Form S-3 (File No. 333-264299), plus the shares of Common Stock exercisable upon exercise of Tranche A warrants and Tranche B warrants.

     

     

    2

     

     

    1.

    NAMES OF REPORTING PERSONS

     

    Vivo Opportunity, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     (a) ☐

     (b) þ

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    12,500,000 (1)(2)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    12,500,000 (1)(2)

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    12,500,000 (1)(2)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    7.0% (2)

    12.

    TYPE OF REPORTING PERSON

     

    OO

     

    (1) The number represents (i) 6,250,000 shares of Common Stock issuable upon exercise of Tranche A warrants that are exercisable within 60 days of this Statement, and (ii) 6,250,000 shares of Common Stock issuable upon exercise of Tranche B warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.  The Tranche A warrants and Tranche B warrants contain provisions preventing the warrants from being exercised if such exercise would result in the holder obtaining greater than 9.99% of the Issuer’s voting securities.

     

    (2) Based on 167,095,337 shares of the Issuer’s Common Stock to be outstanding after the at the market offering of the Issuer, as disclosed in the prospectus filed by the Issuer on November 7, 2023, pursuant to Rule 424(b)(5), which forms part of the Issuer’s Registration Statement on Form S-3 (File No. 333-264299), plus the shares of Common Stock exercisable upon exercise of Tranche A warrants and Tranche B warrants.

     

    3

     

     

    Item 1. Issuer

     

      (a) Name of Issuer:
        Clene, Inc. (the “Issuer”)
         
      (b) Address of Issuer’s Principal Executive Offices:
        6550 South Millrock Drive, Suite G50 Salt Lake City, Utah, 84121

     

    Item 2. Filing Person

     

    (a) – (c)Name of Persons Filing; Address; Citizenship:

     

      (i)  Vivo Opportunity Fund Holdings, L.P., a Delaware limited partnership; and
      (ii) Vivo Opportunity, LLC, a Delaware limited liability company. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
       
    The address of the principal business office of the Reporting Persons is 192 Lytton Avenue, Palo Alto, CA 94301.
       
    (d) Title of Class of Securities:
      Common Stock, par value $0.0001 per share (“Common Stock”).
       
    (e) CUSIP Number:
      185634102

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    (a) ☐  Broker or dealer registered under Section 15 of the Act;
         
    (b) ☐  Bank as defined in Section 3(a)(6) of the Act;
         
    (c) ☐  Insurance company as defined in Section 3(a)(19) of the Act;
         
    (d) ☐  Investment company registered under Section 8 of the Investment Company Act of 1940;
         
    (e) ☐  An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f) ☐  An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
         
    (g) ☐  A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
         
    (h) ☐  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ☐  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
         
    (j) ☐  A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
         
    (k) ☐  Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
         
      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    4

     

     

    Item 4.Ownership.

     

      (a) and (b)  Amount beneficially owned:
         
        The information set forth in rows 5 through 11 of the cover pages is incorporated by reference into this Item 4. 
         
        The shares reported in this Schedule 13G/A include (i) 6,250,000 shares of Common Stock issuable upon exercise of Tranche A warrants that are exercisable within 60 days of this Statement, and (ii) 6,250,000 shares of Common Stock issuable upon exercise of Tranche B warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. 
         
        The Tranche A warrants and Tranche B warrants contain provisions preventing the warrants from being exercised if such exercise would result in the holder obtaining greater than 9.99% of the Issuer’s voting securities.
         
      (c) Number of shares as to which such person has:

     

    Reporting Person  Sole Voting Power   Shared Voting Power   Sole Dispositive Power   Shared Dispositive Power   Percentage of Common Stock Outstanding 
    Vivo Opportunity Fund Holdings, L.P.   12,500,000    0    12,500,000    0    7.0%*
    Vivo Opportunity, LLC   12,500,000    0    12,500,000    0    7.0%*

     

    * The percent of class was based on 167,095,337 shares of the Issuer’s Common Stock to be outstanding after the at the market offering of the Issuer, as disclosed in the prospectus filed by the Issuer on November 7, 2023, pursuant to Rule 424(b)(5), which forms part of the Issuer’s Registration Statement on Form S-3 (File No. 333-264299), plus the shares of Common Stock exercisable upon exercise of Tranche A warrants and Tranche B warrants.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 13, 2024

     

    VIVO OPPORTUNITY FUND HOLDINGS, L.P,  
       
    By: Vivo Opportunity, LLC  
    Its: General Partner  
       
    /s/ Kevin Dai  
    Name: Kevin Dai  
    Title: Managing Member  
       
    VIVO OPPORTUNITY, LLC  
       
    /s/ Kevin Dai  
    Name:   Kevin Dai  
    Title: Managing Member  

     

     

    6

     

     

    Get the next $CLNN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLNN

    DatePrice TargetRatingAnalyst
    10/4/2022Outperform → Perform
    Oppenheimer
    7/18/2022$16.00Buy
    H.C. Wainwright
    5/2/2022$10.00Buy
    Canaccord Genuity
    9/28/2021$20.00Outperform
    Oppenheimer
    More analyst ratings

    $CLNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Mclaughlin Vallerie

    4 - Clene Inc. (0001822791) (Issuer)

    8/15/25 9:14:11 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Matlin David J

    4 - Clene Inc. (0001822791) (Issuer)

    8/15/25 9:12:43 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kiernan Matthew

    4 - Clene Inc. (0001822791) (Issuer)

    8/15/25 9:11:22 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    SEC Filings

    View All

    Clene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Clene Inc. (0001822791) (Filer)

    8/14/25 8:41:09 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Clene Inc.

    10-Q - Clene Inc. (0001822791) (Filer)

    8/14/25 8:02:45 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Clene Inc. (0001822791) (Filer)

    7/3/25 4:36:43 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Matlin David J bought $438,458 worth of shares (92,307 units at $4.75), increasing direct ownership by 26% to 444,491 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    10/2/24 12:58:21 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Science Officer Mortenson Mark bought $97,432 worth of shares (20,512 units at $4.75), increasing direct ownership by 243% to 28,949 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    10/1/24 4:17:45 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Etherington Robert Dee bought $47,500 worth of shares (10,000 units at $4.75), increasing direct ownership by 33% to 40,149 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    10/1/24 4:17:06 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Clene downgraded by Oppenheimer

    Oppenheimer downgraded Clene from Outperform to Perform

    10/4/22 8:58:30 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Clene with a new price target

    H.C. Wainwright initiated coverage of Clene with a rating of Buy and set a new price target of $16.00

    7/18/22 7:19:07 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Clene with a new price target

    Canaccord Genuity initiated coverage of Clene with a rating of Buy and set a new price target of $10.00

    5/2/22 9:11:11 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live stream

    MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, August 20, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered

    8/20/25 7:00:00 AM ET
    $ADVM
    $CLNN
    $DERM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Diversified Commercial Services

    Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream

    MIAMI, Aug. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter. Day 1August 20, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to the reg

    8/19/25 7:00:00 AM ET
    $ADVM
    $CLNN
    $DERM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Diversified Commercial Services

    Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

    Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its large NIH-sponsored Early Access Protocol early in the fourth quarter of 2025A second Type C meeting has been scheduled with the FDA in the third quarter of 2025 to review the survival benefit associated with CNM-Au8 dosingThe Company expects to submit a New Drug Application in the fourth quarter of 2025 for potential accelerated approval of CNM-Au8® in ALSA Type B end-of-Phase 2 FDA meeting has been scheduled in the third quarter of 2025 to discuss the MS clinical development programCash and cash equivalents of $7.3 million as of June 30, 2025, together

    8/14/25 8:38:15 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Financials

    Live finance-specific insights

    View All

    Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial

    The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeksPrespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose demonstrated a >90% reduction in risk of death or risk of death/permanently assisted ventilation at 24 weeks Survival signal consistent with prior results from the Phase 2 RESCUE-ALS trialClene will continue the open-label extension of CNM-Au8 in the Healey ALS Platform Trial and is in discussions with the Healey & AMG ALS Center to design and offer an Expanded Access Protocol (EAP) of CNM-Au8 30mg for eligible participants of closed regimens and othersClene is pursuing multiple paths, including ongoi

    10/3/22 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3

    SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will report topline results of the CNM-Au8® regimen of the HEALEY ALS Platform Trial on Monday, Oct. 3. Clene's management team will host a conference call and webcast to discuss the results. Conference Call and Webcast DetailsTime and Date: 8:30 a.m. EDT on Oct. 3, 2022Investors: 1 (888) 660-6179 (toll-free) or 1 (929) 203-1946 (toll)Conference ID: 5318408Webcast Link A live audio

    9/30/22 4:12:25 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis

    CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mITT populationConsistent improvements favoring CNM-Au8 were seen across paraclinical biomarkers, providing physiological evidence for its potential neuroprotective and remyelinating effectsCNM-Au8 treatment was well-tolerated, and there were no significant safety findings reportedResults provide support to advance CNM-Au8 into Phase 3 clinical developmentClene to host a call and webcast at 7:30 am EDT today SALT LAKE CITY, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiarie

    8/15/22 7:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Leadership Updates

    Live Leadership Updates

    View All

    Clene Appoints Neurology Expert to Executive Team

    SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Benjamin Greenberg, M.D., M.H.S. as Head of Medical.    An internationally recognized expert in treating disorders of the central nervous system, Dr. Greenberg brings extensive clinical and research experience to Clene as the company continues its development of CNM-Au8® as a potential treatment for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). "Dr. Green

    3/16/23 9:46:10 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Announces New Chief Financial Officer Morgan Brown

    SALT LAKE CITY, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Morgan Brown as Chief Financial Officer effective Feb. 1, 2022. "Morgan joins the executive team at a pivotal time in Clene's growth," stated Clene's President and CEO, Rob Etherington. "He is a seasoned healthcare executive and public-company biopharma CFO, who has led the out-licensing of commercial stage assets and M&A transactions as well as numerous substantial equity and

    2/1/22 7:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Nanomedicine Appoints Dr. Vallerie McLaughlin to its Board of Directors

    SALT LAKE CITY, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced the appointment of Vallerie V. McLaughlin, MD, to its board as its seventh independent director. Dr. McLaughlin is the Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine, Associate Chief Clinical Officer for Cardiovascular Services of the University of Michigan Medical Group, Associate Chief, Division of Cardiovascular Medicine, and Director of the Pulm

    8/5/21 4:01:00 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Clene Inc.

    SC 13G/A - Clene Inc. (0001822791) (Subject)

    11/14/24 3:32:55 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Clene Inc.

    SC 13G - Clene Inc. (0001822791) (Subject)

    11/14/24 3:26:45 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Clene Inc.

    SC 13D/A - Clene Inc. (0001822791) (Subject)

    10/2/24 4:38:44 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care